Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
View Patent ↗Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
1. A method of treating conditions associated with excess eosinophil production selected from the group consisting of chronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, coeliac disease, eosinophilic gastroenteritis, Churg-Strauss syndrome, eosinophilic myalgia syndrome, hypereosinophilic syndrome, and oedematous reactions, in a human, comprising the step of administering to said human in need thereof an effective amount of a synthetic antibody comprising a heavy chain and a light chain, wherein the framework regions of said heavy and light chains are obtained from at least a first antibody and the amino acid sequences of the complementarity determining regions of the heavy chain comprise in sequential order: 1) CDR 1, comprising the amino acid sequence identified as SEQ ID NO: 7; 2) CDR 2 comprising the amino acid sequence identified as SEQ ID NO: 8, and; 3) CDR 3 comprising the amino acid sequence selected from the group consisting of
(A) SEQ ID NO: 9 and
(B)SEQ ID NO: 14.
2. The method of claim 1 wherein said condition associated with excess eosinophil production is hypereosinophilic syndrome.
3. The method of claim 1 wherein said condition associated with excess eosinophil production is eosinophilic gastroenteritis.
4. The method of claim 1 wherein said condition associated with excess eosinophil production is Churg-Strauss syndrome.
5. The method of claim 1 wherein said condition associated with excess eosinophil production is eosinophilic myalgia syndrome.
6. The method of claim 1 wherein said condition associated with excess eosinophil production is an oedematous reactions.
7. The method of claim 6 wherein said an oedematous reactions is selected from the group of: episodic angiodema, helminth infections, and onchocercal dermatitis.
8. The method of claim 1 wherein the framework regions of said heavy chain comprise: amino acids 1-30, 36-49, 66-97 and 109-119 of SEQ ID NO: 19.
9. The method of claim 1 wherein the framework regions of said light chain comprise: amino acids 1-23, 41-55, 63-94 and 104-113 of SEQ ID NO: 21.